XML 56 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Collaborative Agreements (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 15, 2017
USD ($)
Dec. 24, 2018
Sep. 30, 2018
USD ($)
Sep. 25, 2017
USD ($)
May 26, 2017
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2016
TWD ($)
Jul. 27, 2016
USD ($)
Dec. 31, 2015
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2017
USD ($)
Feb. 23, 2023
shares
Jun. 10, 2022
USD ($)
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Collaborative Agreements (Details) [Line Items]                                
Description of payment settlement               On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:   ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment   ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment   ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment                
Milestone payments royalty percentage                   12.00% 12.00%          
Collaborative agreements, description                 In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK.              
Amount received                           $ 3    
Co-Dev agreement, description   On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.                            
Shares issued (in Shares) | shares                         5,291,667      
BHK Co-Development Agreement [Member]                                
Collaborative Agreements (Details) [Line Items]                                
Milestone payment             $ 31,649,000 $ 10,000,000                
Description of payment settlement               On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:   ● Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment     ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment   ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment   ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment                
Upfront cash payment                 $ 1,000,000              
Percentage of payments under co-development agreement                 10.00%              
Total cash amount           $ 1,000,000     $ 10,000,000              
Collaborative agreements, description                 In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.64 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. In addition to the total of NT$50 million, approximately equivalent to $1.64 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.          
Co-Dev Agreement [Member]                                
Collaborative Agreements (Details) [Line Items]                                
Percentage of payments under co-development agreement         50.00%                      
Compensation amount $ 3,000,000                              
Addition cash payment         $ 3,000,000                      
Additional paid-in capital                       $ 3,000,000        
Amount received                       450,000        
Co-Dev agreement, description   the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene’s Common Stock, at the price of NT$50 (approximately equivalent to $1.64 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.                            
Amount received                       450,000        
Collaborative Agreement [Member]                                
Collaborative Agreements (Details) [Line Items]                                
Percentage of payments under co-development agreement                   50.00% 50.00%          
Total cash amount     $ 3,000,000                          
Compensation amount                   $ 3,000,000 $ 3,000,000          
Licensing rights       $ 3,000,000                        
Research and development expense                       $ 3,000,000        
BioFirst Stock Purchase Agreement [Member]                                
Collaborative Agreements (Details) [Line Items]                                
Amount received                             $ 2,902,911 $ 3,000,000
Shares issued (in Shares) | shares                             414,702 428,571
Amount received                             $ 2,902,911 $ 3,000,000